FREDERICK, Md., August 24, 2011 - SAIC-Frederick Inc. and RemedyMD, Inc. announced today an agreement to implement RemedyMD's InvestigateTM Integrated Research Management System software at the National Cancer Institute (NCI) Advanced Technology Program in Frederick, Md. NCI researchers will use the software to manage and analyze large amounts of research data to accelerate progress against cancer.
The agreement is part of NCI's Advanced Technology Partnerships Initiative, which aims to further NCI's mission by speeding the translation of research discoveries into new treatments for cancer and related diseases. SAIC-Frederick is facilitating these partnerships for NCI as the prime contractor for NCI's federal national laboratory in Frederick.
InvestigateTM integrates a next-generation Laboratory Information Management System (LIMS) and Electronic Laboratory Notebook (ELN) software designed to enable life sciences researchers to quickly and dynamically collect, aggregate, harmonize and analyze data.
InvestigateTM, built on RemedyMD's MosaicTM Platform, offers experiment design and execution, structured and unstructured data management, and biospecimen management. Mosaic weaves together fully web-enabled user-interface technology, persistent data storage, and interface, querying, and reporting tools, all interacting through a rules-based ontology to ensure data harmonization.
During this implementation RemedyMD and SAIC-Frederick will collaborate to improve laboratory workflows, biospecimen management approaches, instrument integration, data visualization, and a research project review and approval system, all aimed at improving operations in the nine laboratories of the NCI Advanced Technology Program and in NCI's Patient Characterization Center.
"SAIC-Frederick is very pleased to be collaborating with the medical research technology experts at RemedyMD. We believe that our cooperative efforts to improve these technologies will lead to powerful new approaches and important insights into genomic, proteomic, and imaging studies," said Dr. Bruce Crise, Director, Business Development at SAIC-Frederick.
"RemedyMD is delighted to collaborate with SAIC-Frederick and NCI on this important project. We look forward to advancing the acceptance of Integrated Research Management Systems in the marketplace as their value in identifying and treating complex disease becomes more evident," said Gary Kennedy, Founder and CEO of RemedyMD.
SAIC-Frederick Inc. is the prime contractor for NCI's research and development center in Frederick, Md. This is a national laboratory dedicated to rapidly translating basic research into new technologies for diagnosing, treating, and preventing cancer and AIDS. SAIC-Frederick conducts basic research and maintains a full suite of advanced technologies in areas such as nanotechnology, genomics, proteomics, and imaging. The company operates the federal government's drug and vaccine manufacturing facilities; operates the high-performance Advanced Biomedical Computing Center; and supports more than 300 clinical trials for patients in the United States and around the world. SAIC-Frederick is a wholly owned subsidiary of SAIC, a Fortune 500(r) company (NYSE: SAI).
Information about NCI's Advanced Technology Partnerships Initiative can be found at http://atp.ncifcrf.gov/atpi/.
RemedyMD is the technology leader in delivering registries, software to build registries, and registry-based applications for life science research. RemedyMD's tools and applications help researchers aggregate data from widely disparate sources, harmonize that data through an extensive rules-based ontology, and analyze information through powerful querying and reporting tools. RemedyMD solutions enable improved scientific and clinical research, leading to more effective translational research, personalized medicine, and accountable care.
Information about RemedyMD, including the Investigate(tm) product, can be found at http://www.remedymd.com.